Daejeon, South Korea

Heeyung Cho


Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Heeyung Cho: Innovator in Pharmaceutical Chemistry

Introduction

Heeyung Cho, based in Daejeon, South Korea, is a distinguished inventor recognized for his contributions to pharmaceutical chemistry. With a focus on developing innovative compounds, Cho has garnered attention for his work involving 3-aryl-3-methyl-quinoline-2,4-diones, which hold promise in treating central nervous system disorders.

Latest Patents

Heeyung Cho holds a patent for his invention titled "3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof, and pharmaceutical composition containing the same." This patent pertains to compounds that act as 5HT6 receptor antagonists, demonstrating exceptional binding affinity and selectivity for the 5HT6 receptor compared to others. The implications of this invention are significant, providing potential therapeutic avenues for disorders associated with the 5HT6 receptor.

Career Highlights

Cho is affiliated with the Korea Research Institute of Chemical Technology, where he has been instrumental in advancing research on chemical compounds with medicinal properties. His dedication to the field of pharmaceutical innovation has established him as a valuable asset to his organization.

Collaborations

Throughout his career, Heeyung Cho has collaborated with notable colleagues such as Churlmin Seong and Nosang Park. Their joint efforts have enhanced the research landscape and fostered advancements in developing new pharmaceutical solutions.

Conclusion

Heeyung Cho exemplifies the spirit of innovation within the realm of pharmaceutical chemistry. His patent not only showcases his inventive capabilities but also highlights the importance of collaboration in achieving advancements that may significantly impact the treatment of central nervous system disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…